Riboflavin 5'-phosphate
As of the edition of 20 October 2026, Riboflavin 5'-phosphate is a small molecule: marketed, first approved in 1985 (US); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1985
- Kind
- Small molecule
- Brand name
- M.V.I.-12 Adult
- First approved
- 8 August 1985 (US)
- Approvals on record
- 14 in 1 region
- Holder of the most recent approval
- Glaukos; 7 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Eye
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Glaukos holds a later exclusivity on its own new formulation or combination product, ending 2028; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Glaukos | Acquired holder | 2020 to now |